Compare MIR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | NUVL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.1B |
| IPO Year | N/A | 2021 |
| Metric | MIR | NUVL |
|---|---|---|
| Price | $24.53 | $104.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $28.29 | ★ $134.29 |
| AVG Volume (30 Days) | ★ 3.3M | 828.0K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $902,300,000.00 | N/A |
| Revenue This Year | $8.15 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $243.04 | ★ N/A |
| Revenue Growth | ★ 7.82 | N/A |
| 52 Week Low | $12.00 | $55.54 |
| 52 Week High | $30.28 | $112.88 |
| Indicator | MIR | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 52.26 |
| Support Level | $24.52 | $103.83 |
| Resistance Level | $26.36 | $107.99 |
| Average True Range (ATR) | 1.03 | 3.38 |
| MACD | 0.02 | -0.87 |
| Stochastic Oscillator | 31.93 | 12.44 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.